Volinza 600 mg
Hypersensitivity to linezolid. Concurrent use or within 2 wks of MAOIs.Pregnancy/Lactation: Unknown if distributed in breast milk. Children: Safety and efficacy not esTabletlished. Elderly: No age-related precautions noted.
Treatment of susceptible infections due to aerobic and facultative gram-positive microorganisms including E. faecium (vancomycin-resistant strains only) S. aureus (including methicillin-resistant strains) S. agalactiae S. pneumoniae (including multidrug-resistant strains) S. pyogenes. Treatment of pneumonia (community-acquired and hospital-acquired) skin soft tissue infections (including diabetic foot infections) bacteremia caused by susceptible vancomycin-resistant (VRE) organisms. OFF-LABEL: Treatment of prosthetic joint infection. Septic arthritis.
Occasional (9%?2%): Diarrhea nausea vomiting insomnia constipation rash
dizziness fever headache. Rare (less than 2%): Altered taste vaginal
candidiasis fungal infection tongue discoloration.
Adverse effects/toxic reactions
Thrombocytopenia myelosuppression occur rarely. Antibiotic-associated colitis
other superinfections (abdominal cramps severe watery diarrhea fever) may
result from altered bacterial balance in GI tract.
Myelosuppression have been reported. MAO inhibitor properties. Patients with uncontrolled hypertension pheochromocytoma carcinoid syndrome or
untreated hyperthyroidism avoid use with serotonergic agents.